Literature DB >> 24898537

Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.

Klaus Engelke1, Thomas Fuerst, Bernard Dardzinski, John Kornak, Shabana Ather, Harry K Genant, Anne de Papp.   

Abstract

Odanacatib, a selective cathepsin K inhibitor, increases areal bone mineral density (aBMD) at the spine and hip of postmenopausal women. To gain additional insight into the effects on trabecular and cortical bone, we analyzed quantitative computed tomography (QCT) data of postmenopausal women treated with odanacatib using Medical Image Analysis Framework (MIAF; Institute of Medical Physics, University of Erlangen, Erlangen, Germany). This international, randomized, double-blind, placebo-controlled, 2-year, phase 3 trial enrolled 214 postmenopausal women (mean age 64 years) with low aBMD. Subjects were randomized to odanacatib 50 mg weekly (ODN) or placebo (PBO); all participants received calcium and vitamin D. Hip QCT scans at 24 months were available for 158 women (ODN: n = 78 women; PBO: n = 80 women). There were consistent and significant differential treatment effects (ODN-PBO) for total hip integral (5.4%), trabecular volumetric BMD (vBMD) (12.2%), and cortical vBMD (2.5%) at 24 months. There was no significant differential treatment effect on integral bone volume. Results for bone mineral content (BMC) closely matched those for vBMD for integral and trabecular compartments. However, with small but mostly significant differential increases in cortical volume (1.0% to 1.3%) and thickness (1.4% to 1.9%), the percentage cortical BMC increases were numerically larger than those of vBMD. With a total hip BMC differential treatment effect (ODN-PBO) of nearly 1000 mg, the proportions of BMC attributed to cortical gain were 45%, 44%, 52%, and 40% for the total, neck, trochanter, and intertrochanter subregions, respectively. In postmenopausal women treated for 2 years, odanacatib improved integral, trabecular, and cortical vBMD and BMC at all femur regions relative to placebo when assessed by MIAF. Cortical volume and thickness increased significantly in all regions except the femoral neck. The increase in cortical volume and BMC paralleled the increase in cortical vBMD, demonstrating a consistent effect of ODN on cortical bone. Approximately one-half of the absolute BMC gain occurred in cortical bone.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CORTICAL BONE; FEMUR; ODANACATIB; QCT

Mesh:

Substances:

Year:  2015        PMID: 24898537     DOI: 10.1002/jbmr.2292

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  14 in total

1.  The protocol for the Prospective Urban Rural Epidemiology China Action on Spine and Hip status study.

Authors:  Kai Li; Yong Zhang; Ling Wang; Yang-Yang Duanmu; Wei Tian; Hui Chen; Lu Yin; Jian Bo; Yang Wang; Wei Li; Li He; Wen-Hua Zhao; Shao-Qi Xu; Lin-Fen Zhao; Jun Zhou; Feng-Zhe Wang; Yu Liu; Lei Zhu; Yi-Zhong Chen; Xiao-Lin Zhang; Xiao-Guang Hao; Zhi-Wei Shi; Jun-Ying Wang; Ji-Man Shao; Zhi-Jian Chen; Ren-Sheng Lei; Gang Ning; Qian Zhao; Yong-Hong Jiang; Ya-Hong Zhi; Bao-Qing Li; Xiao Chen; Quan-Yong Xiang; Liang Wang; Yuan-Zheng Ma; Shi-Wei Liu; Xiao-Guang Cheng
Journal:  Quant Imaging Med Surg       Date:  2018-08

Review 2.  Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Authors:  Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 3.  Novel advances in the treatment of osteoporosis.

Authors:  Christopher K Y Chan; Alice Mason; Cyrus Cooper; Elaine Dennison
Journal:  Br Med Bull       Date:  2016-08-24       Impact factor: 4.291

Review 4.  Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.

Authors:  Roland D Chapurlat
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-06       Impact factor: 5.346

Review 5.  Perspectives on osteoporosis therapies.

Authors:  E Cairoli; V V Zhukouskaya; C Eller-Vainicher; I Chiodini
Journal:  J Endocrinol Invest       Date:  2015-01-11       Impact factor: 4.256

Review 6.  [Cathepsin K antagonists: preclinical and clinical data].

Authors:  Marion Gamsjäger; Heinrich Resch
Journal:  Wien Med Wochenschr       Date:  2015-01-09

7.  Hip Fracture Discrimination Based on Statistical Multi-parametric Modeling (SMPM).

Authors:  Julio Carballido-Gamio; Aihong Yu; Ling Wang; Yongbin Su; Andrew J Burghardt; Thomas F Lang; Xiaoguang Cheng
Journal:  Ann Biomed Eng       Date:  2019-05-31       Impact factor: 3.934

Review 8.  Value of rare low bone mass diseases for osteoporosis genetics.

Authors:  Alice Costantini; Outi Mäkitie
Journal:  Bonekey Rep       Date:  2016-01-06

Review 9.  Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.

Authors:  T Sugiyama; Y T Kim; H Oda
Journal:  Osteoporos Int       Date:  2014-10-07       Impact factor: 4.507

Review 10.  Male Osteoporosis in the Elderly.

Authors:  Patrizia D'Amelio; Giovanni Carlo Isaia
Journal:  Int J Endocrinol       Date:  2015-09-20       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.